Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

MLA

Troittier, Benoit, et al. “Safety of Enfuvirtide in Combination with an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults over 48 Weeks.” Journal of Acquired Immune Deficiency Syndromes (1999), vol. 40, no. 4, Dec. 2005, p. 413. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.142168232&authtype=sso&custid=ns315887.

APA

Troittier, B., Walmsley, S., Reynes, J., Piliero, P., O’Hearn, M., Nelson, M., Montaner, J., Lazzarin, A., Lalezari, J., Katlama, C., Henry, K., Cooper, D., Clotet, B., Arasteh, K., Delfraissy, J.-F., Stellbrink, H.-J., Lange, J., Kuritzkes, D., Eron, J. J., Jr., … Salgo, M. P. (2005). Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. Journal of Acquired Immune Deficiency Syndromes (1999), 40(4), 413.

Chicago

Troittier, Benoit, Sharon Walmsley, Jacues Reynes, Peter Piliero, Mary O’Hearn, Mark Nelson, Julio Montaner, et al. 2005. “Safety of Enfuvirtide in Combination with an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults over 48 Weeks.” Journal of Acquired Immune Deficiency Syndromes (1999) 40 (4): 413. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.142168232&authtype=sso&custid=ns315887.